Fractionated stereotactic radiotherapy for uveal melanoma, late clinical results

Karin Muller, Nicole Naus, Peter Nowak, Paul Schmitz, C Pan, CA (Cornelis) van Santen, JP Marijnissen, DA Paridaens, Peter Levendag, GPM (Gre) Luyten

Research output: Contribution to journalArticleAcademicpeer-review

36 Citations (Scopus)

Abstract

Purpose: To determine local control, late toxicity and metastatic free survival (MFS) of patients treated with fractionated stereotactic radiation therapy (fSRT) for uveal melanoma (UM). Methods and materials: Between 1999 and 2007, 102 UM patients were included in a prospective study of a single institution (median follow-up (FU) 32 months; median tumor thickness 6 mm); five fractions of 10 Gy were given. Primary endpoints were local tumor control and late toxicity (including visual outcome and eye preservation). Secondary endpoint was MFS. Results: Local tumor control was achieved in 96% of the patients. Fifteen enucleations were performed, 285 months after radiation. Four eyes were enucleated because of local tumor progression. Nine patients developed grade 3 or 4 neovascular glaucoma (NVG), 19 developed severe retinopathy, 13 developed opticoneuropathy grade 3 or 4, 10 developed cataract grade 3, and 10 patients suffered from keratitis sic-ca. Best corrected visual acuity (BCVA) decreased from a mean of 0.26 at diagnosis to 0.16 Conclusions: fSRT is an effective treatment modality for uveal melanoma with a good local control. With that, fSRT is a serious eye sparing treatment modality. However, our FU is relatively short. Also, the number of secondary enucleations is substantial, mainly caused by NVG. (C) 2011 Elsevier Ireland Ltd. All rights reserved. Radiotherapy and Oncology 102 (2012) 219-224
Original languageUndefined/Unknown
Pages (from-to)219-224
Number of pages6
JournalRadiotherapy and Oncology
Volume102
Issue number2
DOIs
Publication statusPublished - 2012

Research programs

  • EMC MM-03-32-04
  • EMC OR-01-60-01

Cite this